Teva Pharma (TEVA) Misses Q1 EPS by 15c, Revenue Beats, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Teva Reports First Quarter 2023 Financial Results and Reaffirms 2023 Non-GAAP Outlook
May 10, 2023 7:00 AM EDTTEL AVIV, Israel--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the quarter ended March 31, 2023.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230510005122/en/
Revenues of $3.7 billion GAAP loss per share of $0.18 Non-GAAP diluted EPS of $0.40 Cash flow used in operating activities of $145 million Free cash flow... More